Recent NIMH clinical trials and implications for practice

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 47, Issue 12, 2008, Pages 1369-1374

  Vitiello, Benedetto ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; METHYLPHENIDATE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ATTENTION DEFICIT DISORDER; AUTISM; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG FORMULATION; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MAJOR DEPRESSION; MONOTHERAPY; NATIONAL HEALTH ORGANIZATION; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUICIDE ATTEMPT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 57749192679     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/CHI.0b013e31818960a7     Document Type: Article

References (27)

1. Vitiello B, Jensen PS. Medication development and testing in children and adolescents. Arch Gen Psychiatry. 1997;54:871-876.
2. RUPP Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;344:1279-1285.
3. RUPP Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314-321.
4. TADS Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescenrs with depression. JAMA. 2004;292:807-820.
5. TADS Team. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64:1132-1144.
6. Brent D, Emslie G, Clarke G et al. The Treatment of Adolescents with SSRI-Resistant Depression (TORDIA): a comparison of switch to venlafaxine or to another SSRI, with or without additional cognitive behavioral therapy. JAMA. 2008;299:901-913.
7. Pediatric Obsessive-Compulsive Treatment Study. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292:1969-1976.
8. Kollins SH, Greenhill LL, Swanson S et al. Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry. 2006;45:1275-1283.
9. Greenhill LL, Abikoff H, Chuang S et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1284-1293.
10. Wigal T, Greenhill LL, Chuang S et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1294-1303.
11. Vitiello B, Abikoff HB, Chuang SZ et al. Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007;17:593-603.
12. Swanson J, Greenhill L, Wigal T et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45:1304-1313.
13. RUPP Autism Network. A randomized controlled crossover trial of methylphenidate in pervasive developmental disorders and hyperactivity. Arch Gen Psychiatry. 2005;62;1266-1274.
14. Emslie GJ, Rush AJ, Weinberg WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031-1037.
15. Brent DA, Holder D, Kolko D et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry. 1997;54:877-885.
16. Kratochvil CJ, Emslie GJ, Silva SG et al. Time to response for depressed adolescents receiving fluoxetine, cognitive-behavioral therapy, or combined treatment. J Am Acad Child Adolesc Psychiatry. 2006;45:1412-1418.
17. Kennard BD, Silva S, Vitiello B et al. Remission and residual symptoms after acute treatment of adolescents with major depressive disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:1404-1411.
18. Vitiello B, Rohde P, Silva SG et al. Effects of treatment on level of functioning, global health, and quality of life in depressed adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:1419-1426.
19. Emslie GJ, Kratochvil CJ, Vitiello B et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry. 2006;45:1440-1455.
20. Domino M, Burns BJ, Silva SG et al. The cost-effectiveness of treatments for adolescent depression: results from the TADS randomized trial. Am J Psychiatry. 2008;165:588-596.
21. Goodyer I, Dubicka B, Wilkinson P et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomized controlled trial. BMJ. 2007;335:142.
22. Clarke G, DeBar L, Lynch F. A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. J Am Acad Child Adolesc Psychiatry. 2005;44:888-898.
23. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164:201-214.
24. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with depression disorders. J Am Acad Child Adolesc Psychiatry. 2007;46:1503-1526.
25. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
26. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63:332-339.
27. Bhatia SK, Rezac AJ, Vitiello B, Sitorius MA, Buehler BA, Kratochvil CJ. Antidepressant prescribing practices for the treatment of children and adolescents. J Child Adolesc Psychopharmacol. 2008;18:70-80.